Member Info for Porter_

Lovely jubbly

That’s your opinion Marty. I took that Eric is just waiting for the patent to come through before anything is announced, to prevent the IP from being infringed on, and perhaps any deals are subject to protection. Anyone would think you were locked out right now old chum.

PP, that’s why I’m so happy to stay long on this investment. I’ve never had such confidence that a start up pharma will deliver. Great names on the board, patent and deals which could land any day. Waiting patiently for the next set of news :)

Agree, we thought 0.06 was cheap, now this is the new cheap. Could easily do 4-5 bags again imo on very little news where the float gets tighter by the day. Wonder if we’ll get another RNS tomorrow before Gad does his panel?

Cheer up Marty

Offgrid, you’re right with the deals. The first deal has already announced today and is noted to be worth billions. Looking good!

“SK biopharmaceuticals has signed a joint research agreement with Insilico Medicine to discover drug candidates for neuroimmune diseases affecting the central nervous system (CNS), in a deal carrying potential milestone payments of up to $2.57 billion and a $4.5 million upfront payment, the company said Monday.

The companies announced the agreement at the BIO International Convention 2026 in Boston.”

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=32129

Probably has a day job

Nice to see the Genflow team being invited to guest speak on the panel, at such a prestigious conference.

Things are definitely hotting up, with the company getting more and more exposure in front of the pharma giants.

Looks like Genflow are finally being recognised as a serious player in the gene therapy industry!

The BIO International Convention 2026 features a heavy presence from global pharmaceutical giants acting as major event sponsors, high-level presenters, and spotlight partnering companies.

Major Pharma Headliners & Sponsors

The top-tier "Double Helix" and "Helix" level sponsors anchors the event with a massive presence on the exhibition floor and within the partnering networks:

Pfizer — Presenting dedicated organizational and sourcing sessions.

Eli Lilly and Company — Hosted by Tim Luker, PhD (VP Lilly Ventures), presenting on cross-functional therapeutic investments.

Merck — Participating as a premium Double Helix sponsor.

Sanofi — Supporting as a high-level sponsor and an integrated partnering spotlight company.

Amgen — Presenting formal company pipelines and acting as a central hub for the event's business development tracks.

Boehringer Ingelheim — Supporting as a lead Helix sponsor with heavily focused partnering modules.

Key Presenting & Partnering Giants

Several other top-20 global biopharma companies are explicitly locked into the event's high-level schedule through executive speakers, presenting slots, and corporate spotlights:

Johnson & Johnson — Actively participating with executive presence, including insights from John Reed, MD, PhD (Executive VP, Corporate R&D).

Roche / Genentech — Highlighted through "Partnering Spotlights" alongside transactional presentations led by Barbara Lückel, PhD (Global Head of Research Technologies Partnering) and Gregg Talbert (Senior VP, Corporate Business Development).

Takeda — Sponsoring major segments with executive presentations by Christopher Arendt, PhD (Chief Scientific Officer) on oncology and neuroscience pipelines.

Novo Nordisk — Functioning as a high-profile partner spotlight and presenting company.

GlaxoSmithKline (GSK) — Scheduled through data and AI partnering tracks led by Daniyal Hussein (Executive Director, Technology Business Development).

Novartis — Sponsoring clinical data and safety strategy sessions led by Jamie Geier, PhD (Global Head of Quantitative Safety).

AstraZeneca — Active across corporate sponsorships and late-stage process development workshops spearheaded by Mahesh Bule (Director of Late-Stage Process Development).

Bristol Myers Squibb (BMS) — Presenting international healthcare policy and market access strategies through Andrew Whitehead (VP, International Market Access).

Chugai Pharmaceutical — Attending and formally listed as a presenting corporate entity.

bio san diego - genflow bio chairman gad berdugo will be participating in an mrna panel during the event. the panel is scheduled for tuesday, june 23, from 7:30am to 9:00am pacific time.

https://www.***************************/genflow-biosciences-to-attend-bio-san-diego-as-chairman-gad-berdugo-joins-mrna-panel/4121254235

Have opened back up the group, let us know when you’re in so we can close it again

Have reopened the telegram group for 24 hours, to let in the core investors. Just search Genflowbio - will revoke the public page again tomorrow.

Hi Pickedpeck, works just been super busy and taking up all my time.

Just deactivated my LinkedIn has have a lot going on, so not ignoring you and will be back 🤝

There shouldn’t be anything in the poster that isn’t already in the investor presentation.

Until the patent is fully awarded, Genflow will want to protect their IP and keep any data limited.

The dog data also requires the peer review of industry experts and if a deal coming, may need to be considerate towards those stakeholders.

Stay positive guys, but don’t read too much into it if we don’t get an update as of yet.

Marty starting the ramp fest 😅😁

I see the options as a positive move, as it reads as though they have a 10 year maturity and can be cancelled if they leave the company. Amazon do a similair thing. Helps to retain good leadership in a very competitive industry and the awards seem appropriate for the roles and work expected of the leadership.

Would also incentivise proactive management, as the only other way they can be activated that I can think of, is through a company takeover, so they will be motivated to find a buyer to cash in the reddies.

I second what money has said.

If you search on google for Peter, he has been subject to notable success in his own areas of expertise in recent years, and this understandably requires great attention. He has been and will no doubt continue to be very supportive of Genflow, but needs to prioritise his workload and commitments.

It’s clear Genflow is now able to walk on its own two legs, so no guilt required in passing the torch onto someone to take it into its next phase.

I wouldn’t pay too much attention to the buy and sell price as based on the pepper trade smoke and mirrors, plus yesterdays price action, that 500k could still be a buy.

We’re now 10 days over when last years AGM was announced. The only logical explanation I can find for that is something big is cooking and they want it over the line before our meeting.

Anyone selling now is crazy in my humble opinion…

Congrats on the wedding PP, she definately had great weather!

I haven’t been messaging as much as been letting Genflow cook, but agree with your thoughts, that this is the warning shot to interested parties, that final offers must be in and agreements signed or once that patent hits, there are no friends in business and best offers will stand, which could include multiples of what may have been paid before the IP became protected.

I’ve seen companies without IP protection but the model concept in place sell for £50m, later to be sold for £bn’s once IP is secured.

We’re not talking small variations in valuations, the difference in market potential can be significant.

I wouldn’t want to be the losing bid when it comes to securing Genflow’s tech!

Thanks rooster. Yes that’s it. Even though a few people invested in Genflow know me, it’s nice to respect each others privacy and not throw out identifiers.